PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea flag South Korea · Delayed Price · Currency is KRW
302,000
+5,000 (1.68%)
Apr 10, 2026, 3:30 PM KST

PharmaResearch Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
175,663165,34867,24572,93141,674
Short-Term Investments
326,108230,48056,54967,9892,000
Trading Asset Securities
112,60141,52336,50543,423113,123
Cash & Short-Term Investments
614,372437,351160,298184,343156,798
Cash Growth
40.48%172.84%-13.04%17.57%97.81%
Accounts Receivable
44,49038,45931,40032,30427,741
Other Receivables
7,3124,0523,3012,757975.32
Receivables
57,26156,56435,99836,23430,490
Inventory
82,70257,32550,23224,45317,342
Prepaid Expenses
1,007950.541,191667.94701.54
Other Current Assets
4,2012,3518,7461,6471,460
Total Current Assets
759,542554,542256,465247,345206,792
Property, Plant & Equipment
174,549147,313123,061117,960109,481
Long-Term Investments
46,26085,81199,10740,71844,911
Goodwill
12,46213,85611,65213,81016,764
Other Intangible Assets
18,06218,30918,82122,72024,825
Long-Term Deferred Tax Assets
7,0798,5574,4768,6673,166
Long-Term Deferred Charges
926.331,2271,5021,2971,200
Other Long-Term Assets
19,98023,74516,25921,10515,715
Total Assets
1,043,888855,701535,281478,055427,647
Accounts Payable
11,47911,0812,8313,5272,939
Accrued Expenses
--974.34860.08702.95
Short-Term Debt
7,9689,35932,34518,86718,873
Current Portion of Long-Term Debt
42.442033.387.4726.52
Current Portion of Leases
1,6252,421628.251,6201,161
Current Income Taxes Payable
35,83023,35511,35710,1366,851
Current Unearned Revenue
-7.8927.6911.36-
Other Current Liabilities
52,85735,89317,70319,14416,751
Total Current Liabilities
109,80182,13765,89954,25348,005
Long-Term Debt
202,940195,865970.7245,35943,385
Long-Term Leases
425.551,121329.91835.481,466
Pension & Post-Retirement Benefits
2,4371,8161,181562.74743.68
Long-Term Deferred Tax Liabilities
1,4792,1562,7943,7414,514
Other Long-Term Liabilities
2,2552,4851,9111,6481,175
Total Liabilities
319,338285,58073,087106,39999,288
Common Stock
5,2555,2555,1605,0565,056
Additional Paid-In Capital
193,566197,312175,428157,582152,413
Retained Earnings
492,071343,061260,787190,862154,018
Treasury Stock
--4,638-4,638-5,260-5,260
Comprehensive Income & Other
-1,561-1,588-3,633-4,737-785.15
Total Common Equity
689,331539,402433,104343,503305,442
Minority Interest
34,54630,03829,09128,15322,917
Shareholders' Equity
724,550570,121462,195371,656328,359
Total Liabilities & Equity
1,043,888855,701535,281478,055427,647
Total Debt
213,001208,78634,30766,76865,611
Net Cash (Debt)
401,371228,565125,991117,57591,187
Net Cash Growth
75.60%81.41%7.16%28.94%94.61%
Net Cash Per Share
36298.6822202.6211932.1711785.889070.92
Filing Date Shares Outstanding
10.3910.3910.29.989.98
Total Common Shares Outstanding
10.3910.3910.29.989.98
Working Capital
649,741472,405190,566193,092158,787
Book Value Per Share
66347.8951917.2842459.1834433.2430617.96
Tangible Book Value
658,807507,238402,631306,974263,854
Tangible Book Value Per Share
63409.9648821.4539471.7930771.4826449.11
Land
28,78221,05118,61718,61714,064
Buildings
81,91879,47081,47280,15152,235
Machinery
60,01552,30541,37530,76627,162
Construction In Progress
50,67431,51012,45912,20032,985
Source: S&P Global Market Intelligence. Standard template. Financial Sources.